Edwards Lifesciences Co. (NYSE:EW) has seen a range of activity with its stock. There has been insider selling of the company's shares, but also positive forecasts from investment firms like Morgan Stanley and Canaccord Genuity Group predicting strong price appreciation. There is evidence of EW's shares being sold by various entities including First Merchants Corp and AustralianSuper Pty Ltd, implying some turbulence. However, the corporation's Q4 earnings beat expectations, demonstrating robust growth and income climbs. Despite this, EW faces an investor class action after losing over $16 billion of market capitalization. Exane Asset Management made a new $585,000 investment in the company, suggesting confidence in the company's potential. Edwards Lifesciences also issued positive earning guidance for Q1 2025 and FY 2025. The company’s focus on heart devices makes it confident in its 2025 outlook. Yet Wolfe Research lowered EW's stock rating, while other firms raised their target prices. Attention to the company’s Q4 earnings and strong growth is notable. Class action lawsuits have been filed against Edwards Lifesciences, and some analysts anticipate a decline in earnings. However, despite stock fluctuations, Edwards' financials appear strong.
Edwards Lifesciences Corp EW News Analytics from Thu, 25 Jul 2024 07:00:00 GMT to Sun, 16 Feb 2025 00:25:19 GMT -
Rating 1
- Innovation -1
- Information 0
- Rumor -3
